Solvay/€SOLB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Solvay
Solvay SA, listed under ticker SOLB, is a Belgium-based international chemical and advanced materials company. It operates through several business segments including Advanced Materials, Advanced Formulations, Performance Chemicals, and Corporate & Business Services. The company was founded in 1863 and has established itself as a key player in producing a wide range of products used in applications such as automotive, electronics, and healthcare.
- Ticker
- €SOLB
- Sector
- Materials
- Primary listing
- BSE
- Employees
- 8,400
- Headquarters
- Brussels, Belgium
- Website
- www.solvay.com
Solvay Metrics
BasicAdvanced
€2.5B
812.67
€0.03
0.25
€1.70
7.15%
Price and volume
Market cap
€2.5B
Beta
0.25
52-week high
€29.70
52-week low
€22.80
Average daily volume
385K
Dividend rate
€1.70
Financial strength
Current ratio
1.15
Quick ratio
0.816
Long term debt to equity
1.637
Total debt to equity
2.013
Dividend payout ratio (TTM)
6,350.00%
Interest coverage (TTM)
3.72%
Profitability
EBITDA (TTM)
587
Gross margin (TTM)
21.38%
Net profit margin (TTM)
0.09%
Operating margin (TTM)
7.98%
Effective tax rate (TTM)
92.37%
Revenue per employee (TTM)
€540,000
Management effectiveness
Return on assets (TTM)
3.69%
Return on equity (TTM)
0.78%
Valuation
Price to earnings (TTM)
812.667
Price to revenue (TTM)
0.544
Price to book
2.39
Price to tangible book (TTM)
34.15
Price to free cash flow (TTM)
6.171
Free cash flow yield (TTM)
16.20%
Free cash flow per share (TTM)
3.855
Dividend yield (TTM)
7.15%
Growth
Revenue change (TTM)
-7.67%
Earnings per share change (TTM)
-97.76%
3-year revenue growth (CAGR)
8.90%
10-year revenue growth (CAGR)
-7.06%
3-year earnings per share growth (CAGR)
-86.74%
10-year earnings per share growth (CAGR)
-38.22%
3-year dividend per share growth (CAGR)
-29.29%
10-year dividend per share growth (CAGR)
-7.83%
What the Analysts think about Solvay
Analyst ratings (Buy, Hold, Sell) for Solvay stock.
Analyst projections of the future price of Solvay stock.
Bulls say / Bears say
Solvay plans to more than double Taiwan capacity for ultra-pure peroxide by the end of 2026 and aims to triple its electronics-grade business over five to seven years. Reuters reports that demand for high-purity peroxide is expected to outpace the wider market, giving this expansion a strong growth driver. (Reuters)
Solvay is investing €15–20 million to expand rare-earth separation at La Rochelle, backed by new customer commitments, and plans industrial-scale dysprosium and terbium production. This could position the company to benefit from demand for non-Chinese supply chains, although the growth will take time to develop. (Solvay)
Solvay delivered €26 million of structural cost savings in the second quarter, with manufacturing efficiencies helping to offset inflation. Continued savings could support margins as markets recover. (Solvay)
After the Saudi peroxide plant remained shut amid the Middle East conflict, Solvay cut its 2026 EBITDA outlook to €720–740 million from €770–850 million and lowered its free-cash-flow range to €120–150 million from at least €200 million. The downgrade shows how prolonged disruption can quickly damage earnings and cash generation. (Solvay, MarketScreener)
Underlying Q2 sales fell 7.4% organically and EBITDA fell 19.5%, as weak seaborne soda-ash pricing and lower volumes weighed on results. Continued softness in these markets could keep earnings under pressure even if the Saudi plant restarts. (Solvay)
First-half free cash flow was only €15 million, down from €97 million a year earlier, while net debt reached €1.8 billion and leverage rose to 2.3 times. That leaves less room to absorb further operating shocks or fund investment without a sustained cash-flow recovery. (Solvay)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
Solvay Financial Performance
Revenues and expenses
Solvay Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Solvay
AllUSDEURGBP
Fund name | Fund size | €SOLB weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.14% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.14% |
iShares MSCI World Small Cap£WLDS | $9B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.